Literature DB >> 16082551

Evaluation of acute pyelonephritis with DMSA scans in children presenting after the age of 5 years.

Neamatollah Ataei1, Abbas Madani, Reza Habibi, Mosa Khorasani.   

Abstract

It is generally believed that infants are more susceptible to development of renal scarring after pyelonephritis than children over 5 years old. This view has led to differences in investigations and treatment according to age. The aim of this prospective study was to assess the occurrence of renal parenchymal lesion in children over 5 years admitted with a first-time symptomatic urinary tract infection (UTI). Between October 2000 and April 2002, 52 children aged over 5 years who were admitted to our department with probable acute pyelonephritis (APN) and a positive urine culture were included in this study. All children received antibiotics for 14 days. During the acute phase of infection, scintigraphy with technetium-99m-labeled dimercaptosuccinic acid (DMSA) and ultrasonography (US) were done. Voiding cystourethrography (VCUG) was performed in all children early in the course of the illness, generally within 5-7 days of hospitalization. When scintigraphy showed renal parenchymal changes, repeat scintigraphy was done after at least 3 months to assess the progression of renal abnormalities. Of the 52 children with a first-time documented pyelonephritis, cortical scintigraphy showed renal lesion in 41 children (78.8%). US was normal in all children with normal renal scintigraphy, while it detected renal abnormalities in 16 of the 41 (39 %) with abnormal scintigraphy (p <0.0001). Topographic analysis of the 165 focal lesions showed that 42.4% were localized to the upper poles, 17.5% to the middle third, and 40% to the lower poles of the kidneys. Repeat scintigraphy showed persistent lesions corresponding to those on the initial scan in nine (28.2%) of the 32 children. Renal lesions had partly regressed in 23 (71.8%) of the patients who underwent repeat scintigraphy. Vesicoureteral reflux was observed in 13.4% of kidneys and renal parenchymal abnormalities were identified in 71.4% and 72.2% of renal units, respectively, with and without reflux ( p >0.05). In conclusion, our data did not confirm the conventional opinion that the risk of renal scarring after pyelonephritis is low in children over the age of 5 years. Our findings suggest that renal scintigraphy may be a more appropriate method of investigation than VCUG for evaluation of the children over 5 years with acute pyelonephritis. Additionally, the frequency of scintigraphic changes is high, and a strategy based exclusively on ultrasound findings would miss about 61% of the abnormal renal units. We recommend that all children, irrespective of age, will benefit from further investigations that might prevent or limit the development of scarring process and renal complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082551     DOI: 10.1007/s00467-005-1925-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  50 in total

Review 1.  Urinary tract infection in paediatrics: the role of diagnostic imaging.

Authors:  I Gordon
Journal:  Br J Radiol       Date:  1990-07       Impact factor: 3.039

2.  Transient pyelonephritic changes on 99mTechnetium-dimercaptosuccinic acid scan for at least five months after infection.

Authors:  B Jakobsson; L Svensson
Journal:  Acta Paediatr       Date:  1997-08       Impact factor: 2.299

3.  Intrarenal reflux and the scarred kidney.

Authors:  G L Rolleston; T M Maling; C J Hodson
Journal:  Arch Dis Child       Date:  1974-07       Impact factor: 3.791

4.  Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up.

Authors:  S H Jacobson; O Eklöf; C G Eriksson; L E Lins; B Tidgren; J Winberg
Journal:  BMJ       Date:  1989-09-16

5.  Evaluation of 99mtechnetium-dimercapto-succinic acid renal scans in experimental acute pyelonephritis in piglets.

Authors:  H G Rushton; M Majd; R Chandra; D Yim
Journal:  J Urol       Date:  1988-11       Impact factor: 7.450

6.  Intrarenal reflux and its relationship to renal scarring.

Authors:  J S Rose; K I Glassberg; K Waterhouse
Journal:  J Urol       Date:  1975-03       Impact factor: 7.450

Review 7.  Nuclear medicine in pediatric urology and nephrology.

Authors:  G N Sfakianakis; E D Sfakianaki
Journal:  J Nucl Med       Date:  1988-07       Impact factor: 10.057

8.  Vesicoureteral reflux: an accurate predictor of acute pyelonephritis in childhood urinary tract infection?

Authors:  M R Ditchfield; J F De Campo; D J Cook; T M Nolan; H R Powell; R Sloane; K Grimwood; S Cahill
Journal:  Radiology       Date:  1994-02       Impact factor: 11.105

9.  Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

10.  A prospective study of cortical scarring in acute febrile pyelonephritis in adults: clinical and bacteriological characteristics.

Authors:  I R Fraser; D Birch; K F Fairley; S John; M Lichtenstein; B Tress; P S Kincaid-Smith
Journal:  Clin Nephrol       Date:  1995-03       Impact factor: 0.975

View more
  17 in total

1.  Vesicoureteral reflux increases the risk of renal scars: a study of unilateral reflux.

Authors:  Joo Hoon Lee; Chang Hee Son; Moo Song Lee; Young Seo Park
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

2.  Urine macrophage migration inhibitory factor (MIF) in children with urinary tract infection: a possible predictor of acute pyelonephritis.

Authors:  Hasan Otukesh; Seyed-Mohammad Fereshtehnejad; Rozita Hoseini; Sepideh Hekmat; Hamid Chalian; Majid Chalian; Arash Bedayat; Reza Salman Yazdi; Saeed Sabaghi; Saeed Mahdavi
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

3.  The results of different diagnostic imaging studies used in children with urinary tract infection.

Authors:  Majida Noori Nasaif; Ahmed Hassan Alghamdi; Jameel Al Ghamdi; Ali Al-Dammas
Journal:  Sudan J Paediatr       Date:  2015

4.  Diagnostic significance of clinical and laboratory findings to localize site of urinary infection.

Authors:  Eduardo H Garin; Fernando Olavarria; Carlos Araya; Monica Broussain; Claudia Barrera; Linda Young
Journal:  Pediatr Nephrol       Date:  2007-03-21       Impact factor: 3.714

Review 5.  Febrile urinary tract infection, vesicoureteral reflux, and renal scarring: current controversies in approach to evaluation.

Authors:  Martin A Koyle; Jack S Elder; Steven J Skoog; Tej K Mattoo; Hans G Pohl; Pramod P Reddy; Jennifer M Abidari; Warren T Snodgrass
Journal:  Pediatr Surg Int       Date:  2011-02-09       Impact factor: 1.827

Review 6.  Vesicoureteral reflux and reflux nephropathy.

Authors:  Tej K Mattoo
Journal:  Adv Chronic Kidney Dis       Date:  2011-09       Impact factor: 3.620

Review 7.  Applying the ALARA concept to the evaluation of vesicoureteric reflux.

Authors:  Richard S Lee; David A Diamond; Jeanne S Chow
Journal:  Pediatr Radiol       Date:  2006-09

8.  Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results.

Authors:  Aggeliki Kotoula; Stefanos Gardikis; Aggelos Tsalkidis; Elpis Mantadakis; Athanassios Zissimopoulos; Katerina Kambouri; Savvas Deftereos; Gregorios Tripsianis; Konstantinos Manolas; Athanassios Chatzimichael; George Vaos
Journal:  Int Urol Nephrol       Date:  2008-10-03       Impact factor: 2.370

Review 9.  Dimercaptosuccinic acid scan or ultrasound in screening for vesicoureteral reflux among children with urinary tract infections.

Authors:  Nader Shaikh; Russell B Spingarn; Stephanie W Hum
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

10.  Urinary interleukin-6 is useful in distinguishing between upper and lower urinary tract infections.

Authors:  Luis Miguel Rodríguez; Belén Robles; José Manuel Marugán; Angeles Suárez; Fernando Santos
Journal:  Pediatr Nephrol       Date:  2007-11-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.